This suppression is independent of plasma cholesterol changes and BW reduction through regulating markers of plaque instability and inflammation including those linked to plaque hemorrhage (CD163), matrix turnover (matrix metalloproteinase (MMP)-3, MMP-13), cholesterol metabolism (prostaglandin I2 synthase (PTGIS), ATP-binding cassette transporter 1 (ABCA1)), leukocyte recruitment (C-C motif chemokine ligand 2 (CCL2), osteopontin (OPN), interleukin (IL)-6), and leukocyte rolling, extravasation and adhesion (vascular cell adhesion molecule (VCAM)-1, E-selectin (SELE)) [16]
10.1021/acs.jmedchem.5c00242 23 DruckerD
During GLP-1RA therapy, sustained hypophagia may further reduce effective micronutrient intake without immediately producing overt deficiency
Some continue seeing small reductions beyond that
Semaglutide is a GLP-1 receptor agonist initially developed to treat type 2 diabetes